Parke, Davis & Company vs. Doctors' Pharmaceuticals, Inc.

In resolving a motion to dismiss for failure to state a cause of action, the court must hypothetically assume the truth of the factual allegations of the complaint. The inquiry is confined to whether, on the basis of those assumed facts, the plaintiff would be entitled to the relief sought; it does not permit the court to rule on the veracity of the allegations or to decide factual matters that require the presentation of evidence. Where the complaint’s averments, taken as true, establish the elements of patent infringement and unfair competition under the applicable statutes, a cause of action is sufficiently stated and dismissal is improper.

Parke, Davis & Company, a Michigan corporation, owned two separate Philippine Letters Patent: No. 50, covering “Chloramphenicol,” and No. 279, covering a compound denominated “Chloramphenicol Palmitate.” In a prior inter partes proceeding, Doctors’ Pharmaceuticals, Inc. secured a compulsory license from the Director of Patents under Patent No. 50 to manufacture, use, and sell medicinal preparations containing “Chloramphenicol.” Doctors’ Pharmaceuticals subsequently marketed “Venimicetin Suspension.” Parke, Davis alleged that, contrary to the product’s labeling which stated the active ingredient was “Chloramphenicol,” Venimicetin Suspension actually contained “Chloramphenicol Palmitate.” The product’s packaging also carried the statement: “First Compulsory License in the Philippines by Parke-Davis Company Detroit Michigan, U.S.A.” Parke, Davis claimed it had never granted any license for the product, and the compulsory license under Patent No. 50 did not and could not cover Chloramphenicol Palmitate or Patent No. 279.

• The Patents: Parke, Davis & Company, a foreign corporation, was the holder of Philippine Letters Patent No. 279, issued on March 21, 1957, for an invention entitled “Therapeutically Valuable Esters and Method for Obtaining the same.” Claim 4 of this patent covered “Chloramphenicol Palmitate.” The company also held Letters Patent No. 50, which covered “Chloramphenicol.” The two patents were separate and distinct.
• Compulsory License: In a prior proceeding before the Philippine Patent Office (Inter Partes Case No. 181), Doctors’ Pharmaceuticals, Inc. had been granted a compulsory license under Letters Patent No. 50, allowing it to manufacture, use, and sell medicinal preparations containing “Chloramphenicol.” The resolution fixing the terms of that compulsory license was not yet final, as a motion for reconsideration was pending. The compulsory license did not involve Patent No. 279 or “Chloramphenicol Palmitate.”
• Allegations of Infringement: The complaint alleged that defendant Doctors’ Pharmaceuticals, Inc. sold and caused to be sold, and defendant V-LAB Drughouse Corporation distributed, a product called “Venimicetin Suspension.” Although the product’s label indicated it contained “Chloramphenicol,” the complaint expressly averred that it actually contained “Chloramphenicol Palmitate,” the substance covered by Claim 4 of Patent No. 279. The sale and distribution were willful and without plaintiff’s consent.
• Allegations of Unfair Competition: The complaint further alleged that defendants’ product labeling and advertising falsely represented: “First Compulsory License in the Philippines by Parke-Davis Company Detroit Michigan, U.S.A.” Plaintiff alleged that this statement was false and misleading because no license, compulsory or otherwise, had been granted for Chloramphenicol Palmitate or under Patent No. 279. The statement was designed to induce purchasers and physicians to believe Venimicetin Suspension was identical to plaintiff’s product, that its active ingredient came from plaintiff, or that it was made under plaintiff’s supervision.
• Motion to Dismiss: Defendants moved to dismiss on the ground of failure to state a cause of action, asserting that the compulsory license under Patent No. 50 authorized them to manufacture and sell products containing chloramphenicol. They argued that their product labels referred only to “Chloramphenicol,” not “Chloramphenicol Palmitate,” and thus the complaint did not state a claim.
• Trial Court’s Dismissal Order: The Court of First Instance dismissed the complaint, reasoning that Chloramphenicol and Chloramphenicol Palmitate were “the same, the difference being merely in the taste.” It concluded that finding infringement would nullify the compulsory license. On unfair competition, the court held that the Director of Patents’ resolution required defendants to use their own trademarks, negating any falsity.

• Error in Standard of Review: Plaintiff argued that the trial court erred by failing to hypothetically admit the truth of the complaint’s factual allegations, as required when ruling on a motion to dismiss for failure to state a cause of action. The court instead ruled against the veracity of the allegation that Chloramphenicol and Chloramphenicol Palmitate are entirely different substances.
• Separate Patents for Distinct Substances: Plaintiff maintained that the existence of two separate patents—No. 50 and No. 279—covering the two substances demonstrated their distinctness, a matter that could not be judicially noticed and required the presentation of evidence.
• Sufficiency of Infringement Allegations: Plaintiff asserted that, assuming the truth of its allegations, the unauthorized sale of a product containing Chloramphenicol Palmitate constituted patent infringement under Sections 37 and 42 of Republic Act No. 165.
• Sufficiency of Unfair Competition Allegations: Plaintiff contended that defendants’ false representation regarding a compulsory license and the mislabeling of the product’s active ingredient constituted unfair competition under Section 29 of Republic Act No. 166.

• Compulsory License Authorization: Defendants argued that the complaint stated no cause of action because Doctors’ Pharmaceuticals, Inc. had been granted a compulsory license under Patent No. 50 to manufacture, use, and sell its own brands of medicinal preparations containing “chloramphenicol,” which purportedly covered the product in question.
• Labeling Reflects Licensed Substance: Defendants maintained that their product labels and packaging indicated “Chloramphenicol” as the active ingredient, not “Chloramphenicol Palmitate,” and that the substance involved was therefore the licensed one, rendering the infringement claim baseless.

• Sufficiency of the Complaint: Whether the Court of First Instance correctly dismissed the complaint for failure to state a cause of action, considering that the determination required resolving the factual dispute over whether “Chloramphenicol” and “Chloramphenicol Palmitate” are distinct substances, rather than hypothetically admitting the complaint’s allegations as true.

• Sufficiency of the Complaint: The dismissal order was set aside because the trial court applied an incorrect standard. When resolving a motion to dismiss for lack of cause of action, the court must hypothetically assume the truth of the complaint’s factual allegations and determine whether the plaintiff would be entitled to relief on that assumption. The trial court disregarded this rule by ruling against the veracity of the allegation that Chloramphenicol and Chloramphenicol Palmitate are different substances, concluding instead that they are the same. Such a factual conclusion could not be reached without formal evidence, nor could the difference between two separately patented substances be judicially noticed. Had the trial court hypothetically admitted the truth of the allegations — that the two substances are entirely different, that Venimicetin Suspension actually contains Chloramphenicol Palmitate not covered by the compulsory license, and that defendants made false statements about holding a license — the complaint would have stated a valid cause of action both for patent infringement under Sections 37 and 42 of Republic Act No. 165 and for unfair competition under Section 29 of Republic Act No. 166. Thus, dismissal for failure to state a cause of action was erroneous.

• Hypothetical Admission Rule on Motion to Dismiss — In resolving a motion to dismiss a complaint on the ground of failure to state a cause of action, the court must hypothetically admit the truth of the factual allegations set forth in the complaint, except allegations of facts whose falsity the court may properly take judicial notice of. The court’s function is limited to determining whether, upon the assumed facts, the plaintiff is entitled to the relief demanded. The court may not rule upon the veracity of the allegations or resolve factual disputes without a formal offer of evidence. The existence of two separate patents covering two substances precludes judicial notice of their identity and necessitates a trial on the merits.

• “It is axiomatic that in resolving a motion to dismiss a complaint on the ground of failure to state a cause of action, the court should hypothetically assume the truth of the factual allegations of the complaint (except allegations of facts the falsity of which the court may take judicial notice of) and determine whether on the basis thereof, the complainant is entitled to the relief demanded.”
• “Had the lower court applied the foregoing formula, it would not have dismissed, on the ground of failure to state a cause of action, the complaint for damages for infringement of patent and unfair competition. For, instead of hypothetically assuming the truth of the factual allegations of the complaint, the lower court had ruled against their veracity and consequently concluded that the complaint states no cause of action.”
• “The existence of two patents separately covering said substances simply militates against said factual assumption and requires the presentation of evidence sufficient to convince the court that said substances are indeed the same.”

• N/A — The decision does not cite prior case law; the resolution rests entirely on a direct application of the rule on motions to dismiss.

• Section 37, Republic Act No. 165 (Patent Law) — Defines the exclusive rights of a patentee to make, use, and sell the patented article or product, and provides that unauthorized making, using, or selling constitutes patent infringement. The complaint alleged defendants’ unauthorized sale of Chloramphenicol Palmitate, which, if true, fell squarely within this provision.
• Section 42, Republic Act No. 165 — Authorizes a patentee to bring a civil action for damages and injunction against an infringer. The complaint sought these remedies, and assuming the allegations, a valid cause of action was stated.
• Section 29, Republic Act No. 166 (Trademark Law) — Declares as unfair competition, among others, any false statement made in the course of trade. The complaint’s allegations of false representation regarding a compulsory license, if taken as true, constituted a cause of action under this provision.

Barredo (Chairman), Aquino, Guerrero, and De Castro, JJ., concurred. (Justice Guerrero was designated to sit in the Second Division in lieu of Justice Hermogenes Concepcion, Jr., who was on official leave.)

• N/A — The decision was unanimous; no dissenting opinion was recorded.